591 related articles for article (PubMed ID: 29511902)
1. Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors.
Kottschade LA
Curr Oncol Rep; 2018 Mar; 20(3):24. PubMed ID: 29511902
[TBL] [Abstract][Full Text] [Related]
2. Supportive care for patients undergoing immunotherapy.
Rapoport BL; van Eeden R; Sibaud V; Epstein JB; Klastersky J; Aapro M; Moodley D
Support Care Cancer; 2017 Oct; 25(10):3017-3030. PubMed ID: 28707167
[TBL] [Abstract][Full Text] [Related]
3. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.
Nagai H; Muto M
Int J Clin Oncol; 2018 Jun; 23(3):410-420. PubMed ID: 29516216
[TBL] [Abstract][Full Text] [Related]
4. Managing Adverse Events With Immune Checkpoint Agents.
Dadu R; Zobniw C; Diab A
Cancer J; 2016; 22(2):121-9. PubMed ID: 27111908
[TBL] [Abstract][Full Text] [Related]
5. Neurological toxicities associated with immune-checkpoint inhibitors.
Touat M; Talmasov D; Ricard D; Psimaras D
Curr Opin Neurol; 2017 Dec; 30(6):659-668. PubMed ID: 28938341
[TBL] [Abstract][Full Text] [Related]
6. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
7. [The pathology of adverse events with immune checkpoint inhibitors].
Koelzer VH; Glatz K; Bubendorf L; Weber A; Gaspert A; Cathomas G; Lugli A; Zippelius A; Kempf W; Mertz KD
Pathologe; 2017 May; 38(3):197-208. PubMed ID: 28421272
[TBL] [Abstract][Full Text] [Related]
8. Do immune-related adverse events correlate with response to immune checkpoint inhibitors?
Saleh K; Khalife-Saleh N; Kourie HR
Immunotherapy; 2019 Mar; 11(4):257-259. PubMed ID: 30678551
[No Abstract] [Full Text] [Related]
9. Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): An emerging challenge.
Kostine M; Chiche L; Lazaro E; Halfon P; Charpin C; Arniaud D; Retornaz F; Blanco P; Jourde-Chiche N; Richez C; Stavris C
Rev Med Interne; 2017 Aug; 38(8):513-525. PubMed ID: 28214182
[TBL] [Abstract][Full Text] [Related]
10. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
[TBL] [Abstract][Full Text] [Related]
11. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience.
Fujii T; Colen RR; Bilen MA; Hess KR; Hajjar J; Suarez-Almazor ME; Alshawa A; Hong DS; Tsimberidou A; Janku F; Gong J; Stephen B; Subbiah V; Piha-Paul SA; Fu S; Sharma P; Mendoza T; Patel A; Thirumurthi S; Sheshadri A; Meric-Bernstam F; Naing A
Invest New Drugs; 2018 Aug; 36(4):638-646. PubMed ID: 29159766
[TBL] [Abstract][Full Text] [Related]
12. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
[TBL] [Abstract][Full Text] [Related]
13. The safety of therapeutic monoclonal antibodies: implications for cancer therapy including immuno-checkpoint inhibitors.
Demlova R; Valík D; Obermannova R; ZdraŽilová-Dubská L
Physiol Res; 2016 Dec; 65(Suppl 4):S455-S462. PubMed ID: 28006927
[TBL] [Abstract][Full Text] [Related]
14. Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy.
King GT; Sharma P; Davis SL; Jimeno A
Drugs Today (Barc); 2018 Feb; 54(2):103-122. PubMed ID: 29637937
[TBL] [Abstract][Full Text] [Related]
15. Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation.
Yang H; Yao Z; Zhou X; Zhang W; Zhang X; Zhang F
Clin Immunol; 2020 Apr; 213():108377. PubMed ID: 32135278
[TBL] [Abstract][Full Text] [Related]
16. Severe neurologic complications of immune checkpoint inhibitors: a single-center review.
Mancone S; Lycan T; Ahmed T; Topaloglu U; Dothard A; Petty WJ; Strowd RE
J Neurol; 2018 Jul; 265(7):1636-1642. PubMed ID: 29761297
[TBL] [Abstract][Full Text] [Related]
17. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
18. The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment.
Sakata Y; Kawamura K; Ichikado K; Shingu N; Yasuda Y; Eguchi Y; Anan K; Hisanaga J; Nitawaki T; Iio M; Sekido Y; Nakano A; Sakagami T
Lung Cancer; 2019 Apr; 130():159-161. PubMed ID: 30885338
[TBL] [Abstract][Full Text] [Related]
19. Acute and Long-term Adverse Events Associated With Checkpoint Blockade.
Davies M
Semin Oncol Nurs; 2019 Oct; 35(5):150926. PubMed ID: 31514992
[TBL] [Abstract][Full Text] [Related]
20. Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.
O'Kane GM; Labbé C; Doherty MK; Young K; Albaba H; Leighl NB
Oncologist; 2017 Jan; 22(1):70-80. PubMed ID: 27534573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
